We are live on ! Find out more

Haleon

HLN

Market cap $43.8B

9.97 USD

+0.29

3%

At close Updated Oct 15, 2:20 PM EDT

1 day

3%

5 days

7.55%

1 month

7.9%

3 months

2.26%

6 months

3.21%

Year to date

-0.3%

1 year

8.49%

5 years

32.93%

10 years

32.93%

About: Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Employees: 24,524

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 52%

Neutral 28%

Negative 20%

Only Excedrin Brings Digital Pet Nostalgia Back with a Headache You Can't Ignore

Nostalgia-fueled experience introduces Excedrin Rapid Relief, providing fast relief of tough pain that starts in as little as 15 minutes Key Takeaways: Excedrin is introducing My Little Headache, a nostalgic digital-pet experience inspired by the handheld toys of the late '90s and early 2000s, capitalizing on the renewed popularity of digital pets among nostalgia-seeking consumers The interactive experience turns headache disruption into a playful, hard-to-ignore virtual pet that escalates through alerts, animations, and reactions As the digital pet becomes increasingly demanding, My Little Headache reminds consumers that headaches do not wait, and neither should relief. With Excedrin Rapid Relief's patented Fast Release Technology starting to provide relief in as little as 15 minutes, the pet transforms alongside the experience, playfully bringing to life the feeling of leaving headache pain behind and getting back to yourself Singer and actor Jesse McCartney helps bridge nostalgia and contemporary culture, reconnecting with longtime fans while building relevance with a new generation WARREN, N.J.

Only Excedrin Brings Digital Pet Nostalgia Back with a Headache You Can't Ignore

Buy Any Of 15 Ideal 'Safer' October Dogs Tenured Over 10 Years

I analyze 84 top Ten-Year tenured dividend dogs, focusing on yield-based selection and free cash flow safety for October 2026. Chimera Investment, Mach Natural Resources, and Matthews International lead projected net gains, with average estimated returns of 48.6% on $10k invested. Fifteen of thirty-six 'safer' dividend dogs meet the IDEAL standard, with annual dividends from $1k invested exceeding their share price.

Buy Any Of 15 Ideal 'Safer' October Dogs Tenured Over 10 Years

24/7 Wall Street

Goldman Sachs Top European Stock Picks Have a Hidden Perk for Income Investors

Goldman Sachs handpicks European stocks with the highest conviction for outperformance, and four of October's top selections carry a benefit most growth-focused investors overlook entirely.

Goldman Sachs Top European Stock Picks Have a Hidden Perk for Income Investors

Proactive Investors

Unilever on JP Morgan positive watch as Haleon faces caution

Unilever PLC (LSE:ULVR) is on JP Morgan's 'positive watch', and Haleon PLC (LSE:HLN, NYSE:HLN) on 'negative watch', ahead of third-quarter reporting by European consumer staples companies. The note adds Givaudan to positive watch alongside Unilever, Heineken N.V.

Unilever on JP Morgan positive watch as Haleon faces caution

Zacks Investment Research

LCUT vs. HLN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Consumer Products - Discretionary sector have probably already heard of Lifetime Brands (LCUT) and Haleon PLC Sponsored ADR (HLN). But which of these two companies is the best option for those looking for undervalued stocks?

LCUT vs. HLN: Which Stock Is the Better Value Option?

Proactive Investors

Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook

Haleon PLC (LSE:HLN, NYSE:HLN), the consumer healthcare group, is expected to reduce its 2026 organic sales growth guidance after UBS forecast a subdued third quarter and limited visibility over the cough and cold season. UBS expects Haleon to report organic sales growth of 3.1% for the three months to September, below Visible Alpha consensus of 3.5% and broadly unchanged from the second quarter.

Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook

Proactive Investors

Deutsche Bank stays bearish on Haleon as growth headwinds mount

Deutsche Bank has reiterated its 'sell' rating on Haleon PLC (LSE:HLN, NYSE:HLN), warning that the consumer health group faces persistent pressure on growth even as it heads into the cold and flu season. The broker kept a 320p price target on the FTSE 100 company, whose brands include Sensodyne and Panadol, against a last close of 342.8p.

Deutsche Bank stays bearish on Haleon as growth headwinds mount

Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs

Consumer health company Haleon has achieved growing sales of products to counter side-effects of weight-loss drugs in the United States, the company said, capitalising on the rising ‌popularity of GLP-1 medication.

Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs

Zacks Investment Research

LCUT or HLN: Which Is the Better Value Stock Right Now?

Investors with an interest in Consumer Products - Discretionary stocks have likely encountered both Lifetime Brands (LCUT) and Haleon PLC Sponsored ADR (HLN). But which of these two stocks offers value investors a better bang for their buck right now?

LCUT or HLN: Which Is the Better Value Stock Right Now?

Proactive Investors

Deutsche Bank expects European consumer staples to underperform as structural pressures mount

European consumer staples stocks are trading at 18-year lows relative to the broader market, yet Deutsche Bank expects the sector to continue to underperform as consumer spending fails to keep pace with nominal economic growth. Analyst Tom Sykes said the bank has repeatedly tested the hypothesis that staples would recover but continues to expect consumer wallets to lag nominal GDP, putting pressure on earnings and valuations relative to the broader market.

Deutsche Bank expects European consumer staples to underperform as structural pressures mount

See News Rankings

Price charts implemented using Lightweight Charts™